Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines.

Open Access
Publisher Website
Google Scholar
Abstract
PNEUMOCOCCAL and influenza infections continue to cause substantial morbidity and mortality,1-5 and immunization against these infections remains an important public health activity. Several major advisory groups recommend the pneumococcal vaccine (Pneumovax)5-7 and the influenza vaccine6-9 for people aged 65 years and older, and research has shown that the vaccines are cost-effective. The pneumococcal vaccine was cost saving in preventing pneumococcal bacteremia among people aged 65 years and older.10 The influenza vaccine was cost saving or the net cost per person vaccinated was about $7# for people aged 65 years and older.11-14 (A number sign [#] denotes that the estimates were adjusted to 1996 dollars15 to the extent information in the original article was available to do so.)